Q32 Bio Inc. filed a prospectus supplement to sell up to $75 million of common stock under its existing Sales Agreement, after exhausting the prior $14.2 million offering.
Key takeaways
Company filed a new prospectus supplement for up to $75 million in at-the-market common stock sales.
Prior $14.2 million offering under the Sales Agreement has been fully sold and terminated.
Shares will be sold through Cantor Fitzgerald & Co. as sales agent.
The offering is made under an effective shelf registration statement on Form S-3.
Goodwin Procter LLP issued a legal opinion on the validity of the shares.